Muscarinic antagonists

Details Muscarinic antagonists Muscarinic antagonists

2005-05-10

2005-05-10

Desai, Rita (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

06890936

ABSTRACT:
The invention described herein are compounds in accordance with formula I:wherein R1, R2, R3, R4, R5, R6, R2, R8, R9, n, X, and Z are as defined herein, pharmaceutical compositions containing at least one compound of formula I, methods of preparation thereof, and methods of treating disorders with at least one compound of formula I or at least one compound of formula I in association with at least one acetylcholinesterase inhibitor.

REFERENCES:
patent: 0456183 (1991-11-01), None
J. Baumgold et al., 3-α-Chlorimperialine: an m2-selective muscarinic receptor antagonist that penetrates into brain,European Journal of Pharmacology, (1994), 251:315-317.
C. Melchiorre et al., Synthesis and Biological Activity of Some Methoctramine-Related Tetraamines Bearing a 11-Acetyl-5, 11-dihydro-6H-pyrido . . . ,J. Med. Chem., (1993), 36:3734-3737.
M. Watson et al., [3H] pirenzepine and (-)-[3H] quinuclidinyl benzilato binding to rat cerebral cortical and cardiac muscarinic cholinergic sites,J. Pharmacol. Exp. Ther., (1986), 237:419-427.
PCT International Search Report dated Apr. 24, 2003 for corresponding PCT Application No. PCT/US/03/12694.

Affiliated with

Also associated with

Rating

Muscarinic antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Muscarinic antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muscarinic antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3371337